High Level Expression of Platelet-derived Endothelial Cell Growth Factor predicts Good Prognosis in Colorectal Cancer Patients by Tsuji Takashi et al.
Acta Med. Nagasaki 47 : 47-52
High Level Expression of Platelet-derived Endothelial Cell Growth 
Factor predicts Good Prognosis in Colorectal Cancer Patients
Takashi TSUJI, Terumitsu SAWAI, Tohru NAKAGOE, Hiroshi YANO, Hirotoshi HASEBA, Hideaki KOMATSU, 
Hisakazu SINDOU, Hidetoshi FUKUOKA, Shigekazu HIDAKA, Shinichi SHIBASAKI, Atsushi NANASHIMA, 
Hiroyuki YAMAGUCHI, Tohru YASUTAKE and Hiroyoshi AYABE
First Department of Surgery, Nagasaki University School of Medicine
 Platelet-derived endothelial cell growth factor (PD-ECGF) 
is one of the angiogenic factors. PD-ECGF expression is ele-
vated in colorectal carcinoma, but its prognostic value does 
not reach a consensus. The aim of this study is to clarify 
the prognostic value of the PD-ECGF expression in colorec-
tal carcinomas. PD-ECGF expression was measured by en-
zyme-linked immunosorbent assay in frozen materials from 
71 colorectal cancer patients who had recived curative re-
section. Patients were divided into high expression and low 
expression groups based on cut-off value. Correlations 
among PD-ECGF expression, clinicopathologic features, and 
disease-free interval were studied by univariate and multi-
variate analysis. To evaluate the origin of PD-ECGF, serial 
sections of 71 tumors were stained for PD-ECGF and CD68. 
PD-ECGF expression in normal mucosa was 34.4 ± 15.5 
(Units/mg protein) and the cut-off value was 65.4 
(mean+2SD). There were no significant correlations between 
clinicopathological features and PD-ECGF expression. The 
disease-free interval for high PD-ECGF expression group 
was significantly longer than that of low expression group 
(P=0.006). A multivariate Cox's regression analysis revealed 
a high PD-ECGF expression as an independent factor for 
better outcome. In immunohistochemical study, almost all 
tumor cells were negative for PD-ECGF, but stromal macro-
phages were predominantly positive for PD-ECGF. In con-
clusion, the PD-ECGF expression measured in this study was 
derived from stromal macrophages. High PD-ECGF expres-
sion was a predictor for favorable outcome after curative 
resection for colorectal cancer. 
     ACTA MEDICA NAGASAKIENSIA 47: 47-52, 2002
Key Words: platelet-derived endothelial cell growth factor, 
            macrophage, prognostic factor, colorectal cancer
Address Correspondence: Takashi Tsuji, M.D. 
First Department of Surgery, Nagasaki University School of 
Medicine, Sakamoto 1-7-1, Nagasaki, 852-8501 Japan 
TEL: +81-95-849-7304 FAX: +81-95-849-7306 
E-mail: bannv@bolero.plala.or.jp
Introduction
 Platelete-derived endothelial cell growth factor (PD-
ECGF) is one of the angiogenic factors. PD-ECGF has 
chemotactic activity for endothelial cells in vitro and 
is angiogenic in vivo'' PD-ECGF expression is elevated 
in several tumor types, including carcinomas of the 
breast Z' , stomach 3' , esophagus, lung, pancreas", and 
colorectum. 
 In colorectal carcinomas, although some reports sug-
gest that high PD-ECGF expression in tumor cells is 
related to poor prognosis 5, 6', but another shows that 
high expression in tumor stromal cells predicts a sig-
nificantly better prognosis". Thus, there is yet no con-
sensus regarding whether PD-ECGF expression is a 
prongostic factor in colorectal carcinomas. 
 The aim of this study is to clarify whether PD-
ECGF expression is an independent prognostic factor 
in patients with colorectal carcinoma. We also esti-




 We studied 71 patients with colorectal cancer who 
underwent curative resection at First Department of 
Surgery, Nagasaki University School of Medicine from 
February 1994 to December 1999. The mean age of 
patients was 64 years (range, 30-83) and 34 patients 
were male and 37 were female. No patients had been 
given preoperative chemotherapy or radiotherapy. 
Thirty-nine tumors were located in the colon and 32 
tumors were localized in the rectum. Pathological clas-
sification, including stage, depth of invasion, histological 
type, lymphatic invasion, venous invasion and lymph 
node metastasis was defined in accordance with the 
General Rules for Clinical and Pathological Studies
on Cancer of the Colon, Rectum and Anus by the 
Japanese Society for Cancer of the Colon and Rectum". 
Twelve tumors were classified as well-differentiated 
adenocarcinomas, 54 tumors as moderately differenti-
ated adenocarcinomas, 2 tumors as poorly differenti-
ated adenocarcinomas, 1 tumor as signet ring cell car-
cinoma, 1 tumor as mucinous carcinoma, and 1 tumor 
as undifferentiated carcinoma. The seventy-one pa-
tients included 13 patients in stage I , 25 in stage 1 1, 
18 in stage Ill a, 12 in stage III b, and 3 in stage IV. 
The median follow-up period was 42 months (mini-
mum, 4.2 months). Sixty patients had received oral 
adjuvant chemotherapy during more than 1 year after 
surgery (HCFU 50, UFT 10). The written informed 
consents were obtained from all patients.
Enzyme-linked immunosorbent assay for Platelet-derived 
endothelial growth factor 
 Total protein extraction from frozen tissues was per-
formed as follows. Frozen materials from primary 
tumor and normal mucosa stored at -80 'C were 
minced by scissors in a micro tube with extraction 
buffer containing a cocktail of three protease inhibi-
tors (l u g/ml of aprotinin and leupeptin, and 0.1mM 
PMSF) and were homogenized by kontes tube with 
pestle for 1 minute. The solution was centrifuged at 
55000g for 45 minutes at 4°C. The supernatant was 
used for further analysis. Total protein concentration 
was analyzed with Bio-Rad protein assay kit (Bio-Rad, 
Tokyo, Japan). The PD-ECGF expression was measured 
by enzyme-linked immunosorbent assay (ELISA). The 
amount of PD-CEGF sandwiched with the two anti-
PD-ECGF monoclonal antibodies (clone 104B and 232-
2) was estimated by measuring its absorbency at 450 
nm. The amount of PD-ECGF was calibrated with that 
measured for the standard solutions".
Immunohistochemical staining of PD-ECGF and CD 68 
 To evaluate the origin of PD-ECGF, 4,u m serial sec-
tions of formalin fixed paraffin embedded tissues of 
71 tumors were stained for PD-ECGF and CD68. Anti-
PD-ECGF monoclonal antibody') (clone 654-1) was do-
nated by Nippon Roche Research Center, Kamakura, 
Japan. For visualizing a macrophage, anti-CD68 mono-
clonal antibody (clone KP1, DAKO, Japan) was used. 
Details for staining methods were described previously').
Statistical analysis 
 Statistical analyses were performed using the com-
puter program STATISTICA (StatSoft, Tulsa, OK, USA).
Fisher's exact probability test or Chi-square test was 
used for univariate analysis of categorical data and 
unpaired Student's-t test was applied for that of con-
secutive data. To estimate the prognostic value of PD-
ECGF expression, the disease-free interval in 71 pa-
tients was studied. The Kaplan-Meier method") was 
used to estimate disease-free survival rate and differ-
ence between survival curves was tested for signifi-
cance using log-rank test"'. Multivariate analysis was 
performed with a Cox's proportional hazard regression 
model in order to assess the effects of different vari-
ables on patient"). A P value < 0.05 was considered to 
indicate statistical significance.
Results
Clinicopathologic features and PD-ECGF expression level
 The mean value and standard deviation (SD) of PD-
ECGF in normal colonic mucosa and in carcinoma was 
34.4 ± 15.5 (range, 16.5-79.2) and 90.9 ± 52.4 (range, 
16.3-250.2) (Units/mg protein), respectively. Tumors 
with synchronous liver metastasis or peritoneal metastasis 
tend to show low PD-ECGF expression, but there were 
no significant correlations between clinicopathological 
features and tumor PD-ECGF expression (Table-1).
Survival analysis and PD-ECGF expression 
 Because the pattern of PD-ECGF expression in nor-
mal mucosa showed normal distribution, we set up 
the cut-off value of tumor PD-ECGF at 65.4 (mean 
value of normal mucosa + 2SD). The high PD-ECGF 
expression was found in 47 cases (66%) and low ex-
pression was detected in 24 cases (34%). There were no 
significant differences in clinicopathologic features be-
tween the high and low PD-ECGF expression groups 
(Table-2). Thirty-nine of 47 patients (83%) with high 
PD-ECGF expression and 21 of 24 patients (86%) with 
low PD-ECGF expression had received adjuvant che-
motherapy. Figure 1 shows the disease-free interval of 
patients with colorectal cancer according to the tumor 
PD-ECGF expression. Patients with high PD-ECGF ex-
pressions had longer disease-free intervals than those 
with low PD-ECGF expressions (P=0.006).
Hematogenous recurrence and PD-ECGF expression 
 Among 71 patients, 15 cases had experienced recur-
rence: hematogenous recurrence in 7, peritoneal recur-
rence in 4, and lymph node / local recurrence in 4 pa-
tients. The frequency of hematogenous recurrence was
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Table 1. Relation between clinicopathologic features and PD-
ECGF expression.
Table 2. Comparison of clinicopatologic features between 
high and low PD-ECGF expression groups.
                                      PD-ECGF 
                        No. of cases P value 
                                  (Unit/mg protein) 
Depth of invasion 
  sm 5 92.1 ± 47.3 n.s * 
  mp 11 77.5 ± 37.7 
  ss 33 91.2 ± 52.9 
  se 17 110.0 ± 61.2 
  si 5 52.1 ± 29.1 
Histological type 
  well, mod 66 90.6 ± 54.1 0.88 
  por,muc,sig,undiff 5 94.4 ± 21.2 
Lymphatic invasion 
  Absent 12 90.3 ± 38.4 0.96 
  Present 59 91.0 ± 55.0 
Venous invasion 
  Absent 27 98.5 ± 46.2 0.34 
  Present 44 86.2 -L 55.8 
Lymph node metastasis 
  Absent 41 87.2 ± 47.6 0.50 
  Present 30 95.8 ± 58.7 
Liver metastasis 
   Absent 69 92.6 ± 52.1 0.10 
   Present 2 30.7 ± 5.0 
Peritoneal metastasis 
   Absent 69 92.2 ± 52.4 0.21 
   Present 2 45.0 ± 25.2 
Stage 
   1 13 84.0 ± 44.2 n.s. 
  II 25 97.3 ± 48.3 
  IIIa 18 89.1 ± 67.6 
  III b 12 99.8 ± 46.6 
  IV 3 41.4 ± 18.9
                        High group Low group 
Variables (n=47) (n=24) P value 
Sex 0.21 
  Male 25 9 
  Female 22 15 
Age at operation 0.80 
  <65 24 13 
  <65 23 11 
Location 0.68 
  Rectum 22 10 
  Colon 25 14 
Maximum size 0.45 
  <5 cm 24 10 
   =<5 cm 23 14 
Macroscopic type 0.08 
   0, 1, 2 45 20 
   3, 4, 5 2 4 
Histological type 0.10 
  well, mod 42 24 
   por, muc, sig, undiff 5 0 
Depth of invasion 0.72 
  sm, mp 10 6 
   ss, se, si 37 18 
Lymph node metastasis 0.11 
  Absent 24 17 
   Present 23 7 
Lymphatic invasion 0.48 
  Absent 9 3 
  Present 38 21 
Venous invasion 0.27 
  Absent 20 7 
  Present 27 17 
Stage 0.07 
   I 7 6 
  II 18 7 
  III a 12 6 
  III b 10 2 
  IV 0 3
Table 3. PD-ECGF expression and hematogenous recurrence.
                 Hematogenous recurrence 
PD-ECGF P Value 
               (+) (-) 
 High 2(4%) 45(96%) 0.04 
 Low 5(24%) 19(76%)
Figure 1. Disease-free interval after curative surgery for pa-
tients with colorectal cancer according to PD-ECGF expression.
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significantly lower in high PD-ECGF group than in 
low PD-ECGF group (Table-3).
High PD-ECGF expression and standard prongostic factors 
for survival
In an univariate Cox's regression analysis, the sur-
vival of patients with colorectal cancers with high PD-
ECGF expression was significantly better than that of 
patients with cancers with low PD-ECGF expression. 
Colorectal cancers with venous invasion were also as-
sociated with significantly lower survival (Table-4). In 
a step-down multivariate analysis, the PD-ECGF ex-
pression was found to be significantly and independ-
ently associated with disease-free survival (Table-5).
Table 4. Prognostic variables for disease-free survival in 
univariate analysis.
    Variables and Categories No. of cases Hazard ratio (95% Cl*) P value 
Sex 
   Male/Female 34/37 0.96 (0.35-2.65) 0.93 
Age at operation 
   <65/655 37/34 0.84 (0.30-2.37) 0.75 
Location 
   Colon/Rectum 32/39 1.11 (0.39-3.13) 0.84 
Maximum size 
   <5cm/5cm5 34/37 0.81 (0.29-2.24) 0.69 
Macroscopic type 
   0,1,2/3,4,5 65/6 2.99 (0.82-10.94) 0.10 
Histological type 
   well,mod/por,muc,sig,undiff 66/5 1.33 (0.30-5.90) 0.71 
Depth of invasion 
   sm,mp/ss,se,si 16/55 2.02 (0.71-5.79) 0.18 
Lymph node metastasis 
   Absent/Present 41/130 1.27 (0.46-3.52) 0.65 
Lymphatic invasion 
   Absent/Present 12/59 5.30 (0.69-40.53) 0.11 
Venous invasion 
   Absent/Present 27/44 3.79 (1.06-13.53) 0.04 
Stage 
   I , II,Ma/IIIb,IV 56/15 2.64 (0.94-7.42) 0.07 
PD-ECGF 
   High/Low 47/24 4.13 (1.46-11.68) 0.007 
*Cl, Confidence interval.
Immunohistochemistry for PD-ECGF and macrophage 
 In immunohistochemical study, tumor cells were 
negative for PD-ECGF expression, with the exception 
of 3 cases (4.2%) in which a few tumor cells were
Table 5. Prognostic variables for disease-free survival in mul-
tivariate Cox's regression analysis.
    Variables Categories Hazard ratio 95% CI* P value 
    PD-ECGF High 1 
                         Low 3.82 1.34-10.89 0.012 
     Stage I, II, h a 1 
                       Mb, IV 2.36 0.82-6.78 0.110 
  Venous invasion Absent 1 
                      Present 2.80 0.77-10.26 0.120 
*CI, Confidence interval.
Figure 2. Immunohistochemical staining of colon carcinoma 
specimens with antibodies to (a) platelet-derived endothelial 
cell growth factor (PD-ECGF), and (b) CD68. (a) PD-ECGF ex-
pression predominantly was present in tumor stroma 
(counterstained with Mayer's hematoxylin, original magnifica-
tion X200). (b) The staining pattern of CD68 was nearly coin-
cident with that of PD-ECGF, suggesting that PD-ECGF positive 
cells predominantly were stromal macrophages (counterstained 
with Mayer's hematoxylin, original magnification X200).
stained. PD-ECGF positive cells predominantly were 
found in the stroma of tumor tissue (Fig. 2a). To char-
acterize the PD-ECGF positive cells, sequential sections 
were immunostained with anti-human CD68 (KP1) an-
tibody, a marker for human macrophages. The stain-
ing pattern of CD68 was nearly coincident with that 
of PD-ECGF (Fig. 2b).
Discussion
 The prognostic value of the PD-ECGF expression in 
colorectal carcinoma does not reach a consensus. Some 
reports suggest that high expression of PD-ECGF in 
tumor cells is related to poor prognosis 5 ,6' , but an-
other shows that high expression in tumor stromal cells 
predicts a significantly better prognosis'). Because 
immunohistochemical study may be a little affected 
by subjectivity, we estimated PD-ECGF expression 
using ELISA. 
 In the current study, low PD-ECGF expression was 
related to hamatogenous metastasis and high PD-
ECGF expression was found to be significantly and in-
dependently associated with better survival. PD-ECGF 
has been demonstrated to be identical to thymidine 
phosphorylase,13' an enzyme involved in pyrimidine nu-
cleoside metabolism that convert 5'-deoxy-5'fluorouridine 
and tegafur to 5-fluorouracil14'. However, because the 
ratio of patients who had received adjuvant chemo-
therapy was not differ between high PD-ECGF expres-
sion group and low PD-ECGF expression group, 
adjuvant chemotherapy could not have an influence 
on the difference of their survival. 
 In immunohistochemical study of colorectal carci-
noma, the main reason for the contradiction in prog-
nostic value of PD-ECGF expression is a difference to 
evaluate the PD-ECGF expression in tumor cells or in 
stromal cells. Takebayashi et al.') estimated PD-ECGF 
stain in cancer cells and high expression was related 
to poor survival. On the other hand, in a recent re-
port, Saito et al." showed that high PD-ECGF expres-
sion in tumor stroma was associated with better sur-
vival. Our data is consistent with them. In present 
study, PD-ECGF positive cells were predominantly 
found in the stroma and most stromal macrophage 
were PD-ECGF positive in immunohistochemistry. One 
reason of this discrepancy in PD-ECGF staining pat-
tern may be difference of monoclonal antibodies used. 
Takahashi et al."' reported that PD-ECGF expression 
originated from stromal macrophage using double-
stainig method for PD-ECGF and CD68 in colorectal 
carcinomas. Recent study using immuno-electron mi-
croscopy for PD-ECGF indicated that the specific
granules of the macrophages in the rectal cancer 
specimens showed positive for PD-ECGF, however, 
tumor cells showed diffuse stains''. 
 What is function of macrophage infiltrating in tu-
mors? It is suggested that tumor-infiltrating macro-
phages produce several angiogenic factors, such as 
vascular endothelial growth factor"', fibroblast growth 
factor's', and tumor necrosis factor- a 19'. Leek et al.20' 
reported that significant correlation between high vas-
cular grade and increased macrophage counts, and in-
creased macrophage counts was associated with poor 
survival in breast cancer. On the other hand, tumor-
infiltrating macrophages also produce the several 
angiogenic inhibitors, such as plasminogen activator-
specific inhibitor 2'and thrombospondin 122'. Recently, 
Dong et al.") showed that tumor-infiltrating macrophages 
produce angiostatin which is inherent angiogenic in-
hibitor. A balance between angiogenic factors and 
angiogenic inhibitors in microenvironment may deter-
mine the effect of tumor-infiltrating macrophages on 
tumor angiogenesis. 
 The angiogenic effect of PD-ECGF is associated with 
2-deoxy-D-ribose, catabolic product of thymidine by 
PD-ECGF/Thymidine phosphorylase ". The significance 
of PD-ECGF expression in tumor-infiltrating macro-
phages is yet unknown"). There may be differences in 
the functional activity of PD-ECGF produced by tumor 
cells and that produced by macrophages. 
 Macrophages are potent antigen-presenting cells, pre-
senting antigens to helper T-cells, with the consequent 
development of an active cytotoxic T-lymphocyte re-
action. A recent study showed that the presence of 
synchronous liver metastasis was correlated inversely 
with the number of macrophages distributed along the 
invasive margin of colorectal carcinoma". 
 In this study, we showed that stromal macrophages 
expressed PD-ECGF and high PD-ECGF expression 
was significantly and independently associated with 
longer disease-free interval in patients with colorectal 
carcinoma. Thus, it is recommended that colorectal 
cancer patients with low PD-ECGF expression must be 
followed up strictly.
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